NCT06585410
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Study sites: 52 to 53
- Notable Eligibility criteria expanded, about 11 wordsv25
- Minor Study sites revised (52)v24
- Minor Study sites: 50 to 52v23
- Notable Eligibility criteria expanded, about 3 words
- Study sites: 49 to 50
- Secondary endpoints revised (6)
Show 19 earlier versionsHide 19 earlier versions
- Minor Site details revised at 1 of 49 sitesv21
- Minor Study sites: 48 to 49v20
- Minor Site details revised at 1 of 48 sitesv19
- Minor Study sites: 47 to 48v18
- Minor Study sites: 45 to 47v17
- Minor Study sites: 41 to 45v16
- Minor Study sites: 40 to 41v15
- Minor Study sites: 39 to 40v14
- Minor Study sites: 30 to 39v13
- Minor Study sites revised (30)v12
- Minor Study sites: 29 to 30v11
- Minor Study sites: 27 to 29v10
- Minor Study sites: 23 to 27v9
- Minor Study sites: 20 to 23v8
- Minor Study sites: 18 to 20v6
- Minor Study sites: 12 to 18v5
- Minor Study sites: 5 to 12v4
- Minor Study sites: 4 to 5v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Jun 3, 2029 to May 3, 2030
- Study sites: 0 to 4
- Start date changed from estimate of Jan 28, 2025 to Jan 2, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Event-Free Survival (EFS) as assessed by the investigator
Timeframe: Up to 1 year
EFS as assessed by the investigator
Timeframe: Up to 3 years
Secondary (6)
Composite Complete Response (CCR) for Target Lesion (TL)
Non-Target Lesions (NTLs) in the Region of the Target Lesion (ROTL)
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Severity of TEAEs
Size of surgical defect
Show 1 moreShow less
Size of biopsy defect
Arms and interventions
Experimental ArmExperimental
Control ArmOther
Drugs: Cemiplimab
Procedures: Standard of care
Sites
53 sites in 2 countries
United States 48, Australia 5